Acute vs. chronic EEG effects in maprotiline- and in clomipramine-treated depressive inpatients and the prediction of therapeutic outcome

Ulrich, G.; Haug, Hans-Joachim; Fähndrich, E

doi:10.1016/0165-0327(94)90020-5

Cited by 29 publications

(16 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the R also exhibited a decrease in the absolute alpha power at the baseline [94]. Further studies [95,96] reported early changes in the alpha band that were shown in R only. A similar study [97] reported that less alpha current source density was associated with non-responders (NR) compared with both R and controls.…”

Section: Alpha Power and Alpha Asymmetrymentioning

confidence: 87%

Review on EEG and ERP predictive biomarkers for major depressive disorder

Mumtaz

Malik

Yasin

et al. 2015

Biomedical Signal Processing and Control

View full text Add to dashboard Cite

Section: Alpha Power and Alpha Asymmetrymentioning

confidence: 87%

Review on EEG and ERP predictive biomarkers for major depressive disorder

Mumtaz

Malik

Yasin

et al. 2015

Biomedical Signal Processing and Control

View full text Add to dashboard Cite

“…In contrast with our previous study, in which we focused on certain specific brain regions (Leuchter et al 2002), we examined data from each recording electrode. We limited our analysis to the theta frequency band (4-8 Hz), because previous work from this and other laboratories has indicated that energy in the theta band is associated most strongly with treatment outcomes in depression Ulrich et al 1984Ulrich et al , 1994.…”

Section: Qeeg Techniquesmentioning

confidence: 99%

Pretreatment neurophysiological and clinical characteristics of placebo responders in treatment trials for major depression

et al. 2004

View full text Add to dashboard Cite

Rationale: High placebo response rates are a confound in treatment trials for major depressive disorder (MDD). A method for prospective identification of placebo responders could enhance the efficiency of clinical trials. Objective: The objective was to identify the neurophysiological, symptomatic, and cognitive characteristics of subjects who were likely to respond to placebo in clinical trials for MDD. Methods: Fifty-one subjects with MDD were treated in clinical trials with either fluoxetine (n=24) or venlafaxine (n=27) versus placebo. All subjects underwent pretreatment assessment with quantitative electroencephalographic (QEEG) power and cordance, as well as symptom ratings and neuropsychological testing. After a 1-week single-blind placebo lead-in, subjects were randomized to double-blind placebo controlled treatment with a medication or placebo. At the end of 8 weeks, the blind was broken and treatment response assessed. Response was defined by a final Hamilton Depression Rating Scale score of ≤10. Results: Of the medication-treated and placebo-treated subjects, 52% (13/25) and 38% (10/26) responded. Placebo responders had lower pretreatment frontocentral cordance in the theta frequency band than all other subjects (P<0.006) and medication responders in particular (P<0.004). Placebo responders also had faster cognitive processing time, as assessed by neuropsychological testing, and lower reporting of late insomnia (P<0.03). Exploratory examination of a multiple variable model for predicting placebo response was conducted using logistic regression, in which these three pretreatment measures accurately identified 97.6% of eventual placebo responders. Conclusions: These findings suggest that combined clinical, neurophysiological, and cognitive assessments of prospective subjects for clinical trials may be useful for identifying MDD subjects who are likely to show robust response to placebo. Prospective validation of these results in a larger, independent sample of subjects is necessary to establish the reliability and usefulness of this method for prospective identification of placebo responders.

show abstract

“…Many methods have been employed to investigate neurobiological predictors of response to antidepressant medications in OCD and major depressive disorder, including neurotransmitter and receptor assays (3-8), neuroendocrine challenge tests (9-13), neurocognitive testing (14, 15), auditory evoked potentials (16), quantitative electroencephalography (17)(18)(19)(20), and pharmacogenetics (21-23). Unfortunately, few of these findings have been replicated, and none have localized specific neuroanatomical substrates for treatment response.…”

Section: (Am J Psychiatry 2003; 160:522-532)mentioning

confidence: 99%

“…Therefore, identification of reliable predictors of responsiveness to SRIs could potentially save patients lengthy trials of medications that are unlikely to be effective and steer treatment toward modalities that have higher probabilities of succeeding. Markers of treatment responsiveness might also provide further clues to the pathophysiology of OCD and major depressive disorder.Many methods have been employed to investigate neurobiological predictors of response to antidepressant medications in OCD and major depressive disorder, including neurotransmitter and receptor assays (3-8), neuroendocrine challenge tests (9-13), neurocognitive testing (14, 15), auditory evoked potentials (16), quantitative electroencephalography (17)(18)(19)(20), and pharmacogenetics (21-23). Unfortunately, few of these findings have been replicated, and none have localized specific neuroanatomical substrates for treatment response.…”

mentioning

confidence: 99%

Differential Brain Metabolic Predictors of Response to Paroxetine in Obsessive-Compulsive Disorder Versus Major Depression

Saxena¹,

Brody²,

Ho³

et al. 2003

AJP

193

139

View full text Add to dashboard Cite

These findings suggest that, although both OCD and major depressive disorder respond to SRIs, the two syndromes have different neurobiological substrates for response. Elevated activity in the right caudate may be a marker of responsiveness to antiobsessional treatment, while lower right amygdala activity and higher midline prefrontal activity may be required for response of depressive symptoms to treatment.

show abstract

Acute vs. chronic EEG effects in maprotiline- and in clomipramine-treated depressive inpatients and the prediction of therapeutic outcome

Cited by 29 publications

References 14 publications

Review on EEG and ERP predictive biomarkers for major depressive disorder

Review on EEG and ERP predictive biomarkers for major depressive disorder

Pretreatment neurophysiological and clinical characteristics of placebo responders in treatment trials for major depression

Differential Brain Metabolic Predictors of Response to Paroxetine in Obsessive-Compulsive Disorder Versus Major Depression

Contact Info

Product

Resources

About